TY - JOUR
T1 - Treating cancer with genetically engineered T cells
AU - Park, Tristen S.
AU - Rosenberg, Steven A.
AU - Morgan, Richard A.
PY - 2011/11
Y1 - 2011/11
N2 - Administration of ex vivo cultured, naturally occurring tumor-infiltrating lymphocytes (TILs) has been shown to mediate durable regression of melanoma tumors. However, the generation of TILs is not possible in all patients and there has been limited success in generating TIL in other cancers. Advances in genetic engineering have overcome these limitations by introducing tumor-antigen-targeting receptors into human T lymphocytes. Physicians can now genetically engineer lymphocytes to express highly active T-cell receptors (TCRs) or chimeric antigen receptors (CARs) targeting a variety of tumor antigens expressed in cancer patients. In this review, we discuss the development of TCR and CAR gene transfer technology and the expansion of these therapies into different cancers with the recent demonstration of the clinical efficacy of these treatments.
AB - Administration of ex vivo cultured, naturally occurring tumor-infiltrating lymphocytes (TILs) has been shown to mediate durable regression of melanoma tumors. However, the generation of TILs is not possible in all patients and there has been limited success in generating TIL in other cancers. Advances in genetic engineering have overcome these limitations by introducing tumor-antigen-targeting receptors into human T lymphocytes. Physicians can now genetically engineer lymphocytes to express highly active T-cell receptors (TCRs) or chimeric antigen receptors (CARs) targeting a variety of tumor antigens expressed in cancer patients. In this review, we discuss the development of TCR and CAR gene transfer technology and the expansion of these therapies into different cancers with the recent demonstration of the clinical efficacy of these treatments.
UR - http://www.scopus.com/inward/record.url?scp=80054680991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054680991&partnerID=8YFLogxK
U2 - 10.1016/j.tibtech.2011.04.009
DO - 10.1016/j.tibtech.2011.04.009
M3 - Review article
C2 - 21663987
AN - SCOPUS:80054680991
SN - 0167-7799
VL - 29
SP - 550
EP - 557
JO - Trends in Biotechnology
JF - Trends in Biotechnology
IS - 11
ER -